AlloVir, Inc.
NASDAQ:ALVR
Overview | Financials
Company Name | AlloVir, Inc. |
Symbol | ALVR |
Currency | USD |
Price | 0.953 |
Market Cap | 109,988,991 |
Dividend Yield | 0% |
52-week-range | 0.58 - 2.485 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Diana M. Brainard M.D. |
Website | https://www.allovir.com |
An error occurred while fetching data.
About AlloVir, Inc.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD